Herbs (Global Traditional) · Ayurveda
Dashamoola (Ten roots formulation)
Moderate Evidencebotanical1 PubMed Study
Hermetica Superfood Encyclopedia
Dashamoola is a classical Ayurvedic formula containing ten medicinal roots that provides anti-inflammatory and analgesic effects through compounds like alkaloids, glycosides, and phenolic compounds. It modulates inflammatory pathways by inhibiting cyclooxygenase enzymes and reducing pro-inflammatory mediators.
Dashamoola is a classical Ayurvedic polyherbal formulation consisting of ten roots from five trees and five shrubs, primarily from plants in the Fabaceae and Solanaceae families native to India. It is traditionally prepared as decoctions (kwath) or fermented forms (Dashamoolarishta) and contains polyphenols, flavonoids, and alkaloids.
Current evidence is limited to preclinical animal models with no human RCTs identified. Key studies include PMID: 25878458 using Wistar rats and Swiss mice demonstrating anti-inflammatory and analgesic effects, and PMID: 29040066 showing benefits in osteoarthritis mice models.
Clinically studied dosages are from animal models only: Dashamoolarishta at 1.8 mL/kg in rats and 2.5 mL/kg in mice. No human dosage guidelines or standardization details are available from clinical research. Consult a healthcare provider before starting any new supplement.
Dashamoola is a classical Ayurvedic polyherbal formulation comprising ten medicinal roots: Bilva (Aegle marmelos), Agnimantha (Clerodendrum phlomidis), Shyonaka (Oroxylum indicum), Patala (Stereospermum suaveolens), Gambhari (Gmelina arborea), Shalaparni (Desmodium gangeticum), Prishnaparni (Uraria picta), Brihati (Solanum indicum), Kantakari (Solanum xanthocarpum), and Gokshura (Tribulus terrestris). As a multi-root botanical blend, it is not typically characterized by conventional macronutrient or micronutrient profiles. Key bioactive compounds include: alkaloids (solamargine, solasonine from Solanum spp., approximately 0.1–0.5% in root extracts), flavonoids (vitexin, orientin from Desmodium gangeticum, ~0.2–0.8% w/w), terpenoids including lupeol and betulinic acid (from Oroxylum indicum and Gmelina arborea, ~0.05–0.3%), saponins (protodioscin from Tribulus terrestris, ~0.5–1.2% in standardized extracts), iridoid glycosides (agnuside, aucubin from Clerodendrum spp., ~0.1–0.4%), phenolic acids (gallic acid, ellagic acid, ~0.1–0.5%), and sesquiterpenes from Aegle marmelos roots (~0.02–0.1%). Fiber content from dried root powder is estimated at 15–25% w/w (crude fiber). Protein content is low, approximately 3–6% w/w in dried root material. Mineral content includes calcium (~500–800 mg/100g dried root), iron (~10–20 mg/100g), magnesium (~150–250 mg/100g), and potassium (~300–500 mg/100g), though these values vary by source and preparation. Bioavailability is enhanced when prepared as decoction (kashaya), as water extraction increases solubility of polar glycosides and phenolics; lipid-soluble terpenoids show improved bioavailability in tailam (oil-based) preparations. Standardization in commercial products typically targets alkaloid and saponin content as marker compounds.
Dashamoola exerts its effects through multiple bioactive compounds including alkaloids, glycosides, and phenolic compounds from its ten root constituents. These compounds inhibit cyclooxygenase (COX) enzymes and lipoxygenase pathways, reducing prostaglandin E2 and leukotriene synthesis. The formulation also demonstrates anti-platelet activity by modulating thromboxane synthesis and platelet aggregation pathways.
Research on dashamoola consists primarily of animal studies demonstrating significant anti-inflammatory effects. Studies showed significant reduction in paw edema (P<0.001) and granuloma weight (P<0.05) comparable to aspirin in animal models. Pain relief studies in mice showed reduced writhing responses (P<0.01) and improved behavioral outcomes in osteoarthritis models (P<0.05). Human clinical trials are limited, and most evidence comes from traditional use and animal research.
Dashamoola is generally considered safe when used traditionally, but comprehensive safety data is limited. The anti-platelet activity may increase bleeding risk when combined with anticoagulant medications like warfarin or aspirin. Individuals with bleeding disorders or scheduled for surgery should exercise caution. Safety during pregnancy and lactation has not been established through clinical studies, though traditional use suggests relative safety under proper guidance.
